Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:PSMD8-MAP3K10

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: PSMD8-MAP3K10
	FusionPDB ID: 69728
	FusionGDB2.0 ID: 69728
		Hgene	Tgene
	Gene symbol	PSMD8	MAP3K10
	Gene ID	5714	4294
	Gene name	proteasome 26S subunit, non-ATPase 8	mitogen-activated protein kinase kinase kinase 10
	Synonyms	HEL-S-91n\|HIP6\|HYPF\|Nin1p\|Rpn12\|S14\|p31	MEKK10\|MLK2\|MST
	Cytomap	19q13.2	19q13.2
	Type of gene	protein-coding	protein-coding
	Description	26S proteasome non-ATPase regulatory subunit 826S proteasome regulatory subunit RPN1226S proteasome regulatory subunit S1426S proteasome regulatory subunit p31epididymis secretory sperm binding protein Li 91nproteasome (prosome, macropain) 26S subuni	mitogen-activated protein kinase kinase kinase 10MKN28 derived nonreceptor_type serine/threonine kinaseMKN28 kinasemixed lineage kinase 2protein kinase MST
	Modification date	20200313	20200313
	UniProtAcc	.	Q02779 Main function of 5'-partner protein: FUNCTION: Activates the JUN N-terminal pathway. {ECO:0000250}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000215071, ENST00000592035, ENST00000602911,	ENST00000593906, ENST00000253055,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	9 X 6 X 6=324	4 X 7 X 3=84
	# samples	9	4
	** MAII score	log2(9/324*10)=-1.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(4/84*10)=-1.0703893278914 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: PSMD8 [Title/Abstract] AND MAP3K10 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: PSMD8 [Title/Abstract] AND MAP3K10 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	PSMD8(38867094)-MAP3K10(40710392), # samples:2
Anticipated loss of major functional domain due to fusion event.	PSMD8-MAP3K10 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PSMD8-MAP3K10 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PSMD8-MAP3K10 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PSMD8-MAP3K10 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	MAP3K10	GO:0018105	peptidyl-serine phosphorylation	19801649
Tgene	MAP3K10	GO:0018107	peptidyl-threonine phosphorylation	19801649

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:38867094/chr19:40710392)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across PSMD8 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across MAP3K10 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000215071

PSMD8

chr19

38867094

ENST00000253055

MAP3K10

chr19

40710392

2887

602

2603

856

ENST00000602911

PSMD8

chr19

38867094

ENST00000253055

MAP3K10

chr19

40710392

2664

379

2380

789

ENST00000592035

PSMD8

chr19

38867094

ENST00000253055

MAP3K10

chr19

40710392

2962

677

510

2678

722

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000215071	ENST00000253055	PSMD8	chr19	38867094	+	MAP3K10	chr19	40710392	+	0.043455478	0.95654446
ENST00000602911	ENST00000253055	PSMD8	chr19	38867094	+	MAP3K10	chr19	40710392	+	0.0580138	0.94198614
ENST00000592035	ENST00000253055	PSMD8	chr19	38867094	+	MAP3K10	chr19	40710392	+	0.073463984	0.926536

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PSMD8-MAP3K10

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
PSMD8	chr19	38867094	MAP3K10	chr19	40710392	379	123	YMAQLKCYYFDYNFGVLLWELLTGEV
PSMD8	chr19	38867094	MAP3K10	chr19	40710392	602	190	YMAQLKCYYFDYNFGVLLWELLTGEV
PSMD8	chr19	38867094	MAP3K10	chr19	40710392	677	56	YMAQLKCYYFDYNFGVLLWELLTGEV

Top

Potential FusionNeoAntigen Information of PSMD8-MAP3K10 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

PSMD8-MAP3K10_38867094_40710392.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-A24:14	DYNFGVLLW	0.6112	0.5874	10	19
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-B47:01	FDYNFGVLL	0.2131	0.6974	9	18
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:10	YFDYNFGV	0.9998	0.6155	8	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:07	YFDYNFGV	0.9998	0.6304	8	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:10	YFDYNFGVL	0.9973	0.5737	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C05:09	YFDYNFGVL	0.9973	0.9049	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:07	YFDYNFGVL	0.9971	0.5767	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C08:15	YFDYNFGVL	0.9951	0.929	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C01:17	YFDYNFGVL	0.9937	0.8881	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C01:30	YFDYNFGVL	0.9731	0.9182	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:13	YFDYNFGVL	0.9618	0.8702	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:29	YFDYNFGVL	0.9572	0.9155	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:10	YFDYNFGVL	0.9442	0.9066	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C08:04	YFDYNFGVL	0.9392	0.8791	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C08:13	YFDYNFGVL	0.9392	0.8791	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:06	YFDYNFGVL	0.9291	0.6364	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:80	YFDYNFGVL	0.9274	0.8785	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:67	YFDYNFGVL	0.9274	0.8785	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C08:03	YFDYNFGVL	0.9142	0.947	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:80	YYFDYNFGV	0.2486	0.8563	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:67	YYFDYNFGV	0.2486	0.8563	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:10	YYFDYNFGV	0.2369	0.8962	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:05	YYFDYNFGV	0.2046	0.8017	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:46	YYFDYNFGV	0.1828	0.6594	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:13	YYFDYNFGV	0.1478	0.8452	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:29	YYFDYNFGV	0.132	0.8603	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C12:16	YYFDYNFGV	0.0934	0.9457	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:27	YYFDYNFGV	0.0615	0.8724	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:10	YFDYNFGVLL	0.9994	0.6234	8	18
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:07	YFDYNFGVLL	0.9993	0.6323	8	18
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:10	YYFDYNFGVL	0.9904	0.5772	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:07	YYFDYNFGVL	0.9892	0.5814	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:14	YFDYNFGVLL	0.9775	0.5543	8	18
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:29	YYFDYNFGVL	0.9476	0.9136	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:13	YYFDYNFGVL	0.9423	0.865	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:05	YYFDYNFGVL	0.9413	0.9091	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:10	YYFDYNFGVL	0.9084	0.9021	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:67	YYFDYNFGVL	0.9074	0.8784	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:80	YYFDYNFGVL	0.9074	0.8784	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:27	YYFDYNFGVL	0.9039	0.9123	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:10	YYFDYNFGVLL	0.9043	0.9102	7	18
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:13	YYFDYNFGVLL	0.8718	0.8536	7	18
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:01	YFDYNFGV	0.9998	0.6304	8	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C18:01	YFDYNFGV	0.9996	0.668	8	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C05:01	YFDYNFGVL	0.9973	0.9049	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:01	YFDYNFGVL	0.9971	0.5767	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:03	YFDYNFGVL	0.997	0.6333	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C18:01	YFDYNFGVL	0.9953	0.5976	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C01:03	YFDYNFGVL	0.9952	0.8138	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C08:02	YFDYNFGVL	0.9951	0.929	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C01:02	YFDYNFGVL	0.9944	0.8862	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C14:02	YFDYNFGVL	0.9832	0.923	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C14:03	YFDYNFGVL	0.9832	0.923	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C03:67	YFDYNFGVL	0.9773	0.971	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C06:06	YFDYNFGVL	0.93	0.9784	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:02	YFDYNFGVL	0.9274	0.8785	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:04	YFDYNFGVL	0.9248	0.8962	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:17	YFDYNFGVL	0.9242	0.9444	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C08:01	YFDYNFGVL	0.9142	0.947	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:04	YFDYNFGVL	0.9034	0.552	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-B53:02	DYNFGVLLW	0.8643	0.5636	10	19
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C18:01	YYFDYNFGV	0.5896	0.6298	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:04	YYFDYNFGV	0.5075	0.628	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-B08:12	YFDYNFGVL	0.493	0.6559	8	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C06:02	YYFDYNFGV	0.4616	0.9904	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C06:17	YYFDYNFGV	0.4616	0.9904	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-B15:13	DYNFGVLLW	0.4044	0.8739	10	19
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:02	YYFDYNFGV	0.2486	0.8563	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C06:06	YYFDYNFGV	0.2211	0.9681	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C06:08	YYFDYNFGV	0.1226	0.9797	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:22	YYFDYNFGV	0.1199	0.5525	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:17	YYFDYNFGV	0.1091	0.946	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C14:02	YYFDYNFGV	0.1075	0.915	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C14:03	YYFDYNFGV	0.1075	0.915	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:04	YYFDYNFGV	0.091	0.8834	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C03:67	YYFDYNFGV	0.0892	0.9694	7	16
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:03	YFDYNFGVLL	0.9995	0.6931	8	18
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:01	YFDYNFGVLL	0.9993	0.6323	8	18
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C18:01	YFDYNFGVLL	0.9986	0.6464	8	18
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:01	YYFDYNFGVL	0.9892	0.5814	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C18:01	YYFDYNFGVL	0.988	0.6025	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:04	YFDYNFGVLL	0.9767	0.6259	8	18
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C03:67	YYFDYNFGVL	0.9762	0.9701	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C04:04	YYFDYNFGVL	0.9544	0.5987	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C14:02	YYFDYNFGVL	0.9476	0.9251	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C14:03	YYFDYNFGVL	0.9476	0.9251	7	17
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	602	HLA-C07:02	YYFDYNFGVL	0.9074	0.8784	7	17

Top

Potential FusionNeoAntigen Information of PSMD8-MAP3K10 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of PSMD8-MAP3K10

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
980	CYYFDYNFGVLLWE	PSMD8	MAP3K10	chr19	38867094	chr19	40710392	602

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PSMD8-MAP3K10

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	980	CYYFDYNFGVLLWE	-7.9962	-8.1096
HLA-B14:02	3BVN	980	CYYFDYNFGVLLWE	-5.70842	-6.74372
HLA-B52:01	3W39	980	CYYFDYNFGVLLWE	-6.83737	-6.95077
HLA-B52:01	3W39	980	CYYFDYNFGVLLWE	-4.4836	-5.5189
HLA-A11:01	4UQ2	980	CYYFDYNFGVLLWE	-10.0067	-10.1201
HLA-A11:01	4UQ2	980	CYYFDYNFGVLLWE	-9.03915	-10.0745
HLA-A24:02	5HGA	980	CYYFDYNFGVLLWE	-6.56204	-6.67544
HLA-A24:02	5HGA	980	CYYFDYNFGVLLWE	-5.42271	-6.45801
HLA-B44:05	3DX8	980	CYYFDYNFGVLLWE	-7.85648	-8.89178
HLA-B44:05	3DX8	980	CYYFDYNFGVLLWE	-5.3978	-5.5112
HLA-A02:01	6TDR	980	CYYFDYNFGVLLWE	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of PSMD8-MAP3K10

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	10	19	DYNFGVLLW	TGATTACAACTTCGGGGTGCTGCTGTG
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	7	16	YYFDYNFGV	CTACTACTTTGATTACAACTTCGGGGT
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	7	17	YYFDYNFGVL	CTACTACTTTGATTACAACTTCGGGGTGCT
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	7	18	YYFDYNFGVLL	CTACTACTTTGATTACAACTTCGGGGTGCTGCT
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	8	16	YFDYNFGV	CTACTTTGATTACAACTTCGGGGT
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	8	17	YFDYNFGVL	CTACTTTGATTACAACTTCGGGGTGCT
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	8	18	YFDYNFGVLL	CTACTTTGATTACAACTTCGGGGTGCTGCT
PSMD8-MAP3K10	chr19	38867094	chr19	40710392	9	18	FDYNFGVLL	CTTTGATTACAACTTCGGGGTGCTGCT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of PSMD8-MAP3K10

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BRCA	PSMD8-MAP3K10	chr19	38867094	ENST00000215071	chr19	40710392	ENST00000253055	TCGA-UL-AAZ6-01A

Top

Potential target of CAR-T therapy development for PSMD8-MAP3K10

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to PSMD8-MAP3K10

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to PSMD8-MAP3K10

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)